

In the Claims

Please cancel Claims 38, 39, 49-51, 53, 55 and 57-150, and add new Claims 151-307.

- Fl
151. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
152. (New) The antibody or antigen-binding fragment of Claim 151, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.
153. (New) The antibody or antigen-binding fragment of Claim 151, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.
- But GI
154. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
155. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
156. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

- Ref G1*
F4 and 11
157. (New) The antibody or antigen-binding fragment of Claim 151, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
158. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
159. (New) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
160. (New) A composition comprising the antibody or antigen-binding fragment of Claim 151 and a physiologically acceptable vehicle or carrier.
- 1/*
161. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 151.
162. (New) The isolated cell of Claim 161, wherein said isolated cell is a hybridoma.
- Ref G2*
163. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
164. (New) The antibody or antigen-binding fragment of Claim 163, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.

- FI
Cont'd
165. (New) The antibody or antigen-binding fragment of Claim 163, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.
166. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
167. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
168. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
169. (New) The antibody or antigen-binding fragment of Claim 163, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
170. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
171. (New) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
- End 627

- Cont'd*
172. (New) A composition comprising the antibody or antigen-binding fragment of Claim 163 and a physiologically acceptable vehicle or carrier.
173. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 163.
174. (New) The isolated cell of Claim 173, wherein said isolated cell is a hybridoma.
175. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.
- Sub-G3*
176. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
177. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
178. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

- But G37*
It cont'd
179. (New) The antibody or antigen-binding fragment of Claim 175, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
180. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
181. (New) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
182. (New) A composition comprising the antibody or antigen-binding fragment of Claim 175 and a physiologically acceptable vehicle or carrier.
183. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 175.
184. (New) The isolated cell of Claim 183, wherein said isolated cell is a hybridoma.
185. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for eotaxin.
- But G47*
186. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.

187. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

188. (New) The antibody or antigen-binding fragment of Claim 185, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

189. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

190. (New) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

191. (New) A composition comprising the antibody or antigen-binding fragment of Claim 185 and a physiologically acceptable vehicle or carrier.

192. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 185.

193. (New) The isolated cell of Claim 192, wherein said isolated cell is a hybridoma.

194. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino

P1
Cont'd
Rev G47

Rev G57

acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

FI
Cont'd
195. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.

Rule 63
196. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

197. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

198. (New) The antibody or antigen-binding fragment of Claim 194, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

199. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

200. (New) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

- P1 Cont'd*
201. (New) A composition comprising the antibody or antigen-binding fragment of Claim 194 and a physiologically acceptable vehicle or carrier.
202. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 194.
203. (New) The isolated cell of Claim 202, wherein said isolated cell is a hybridoma.
204. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
205. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
- Ref G6*
206. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
207. (New) The antibody or antigen-binding fragment of Claim 204, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

208. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
209. (New) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
210. (New) A composition comprising the antibody or antigen-binding fragment of Claim 204 and a physiologically acceptable vehicle or carrier.
211. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 204.
212. (New) The isolated cell of Claim 211, wherein said isolated cell is a hybridoma.
213. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.
214. (New) A composition comprising the antibody or antigen-binding fragment of Claim 213 and a physiologically acceptable vehicle or carrier.
215. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 213.
216. (New) The isolated cell of Claim 215, wherein said isolated cell is a hybridoma.

F/
end

at G7
P

- P/ Cont'd
Sub G27*
217. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.
218. (New) A composition comprising the antibody or antigen-binding fragment of Claim 217 and a physiologically acceptable vehicle or carrier.
219. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 217.
220. (New) The isolated cell of Claim 219, wherein said isolated cell is a hybridoma.
221. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
222. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.
223. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.

- FI
CMT 'L
224. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
225. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
226. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
227. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
228. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
229. (New) The antibody or antigen-binding fragment of Claim 221, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
230. (New) The antibody or antigen-binding fragment of Claim 221, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID

Fl
cont 4

NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

231. (New) A composition comprising the antibody or antigen-binding fragment of Claim 221 and a physiologically acceptable vehicle or carrier.
232. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 221.
233. (New) The isolated cell of Claim 232, wherein said isolated cell is a hybridoma.
234. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
235. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for RANTES.
236. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-3.

237. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
238. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
239. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
240. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
241. (New) The antibody or antigen-binding fragment of Claim 234, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
242. (New) The antibody or antigen-binding fragment of Claim 234, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS

Fl/Art 4
at 65°C, and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

243. (New) A composition comprising the antibody or antigen-binding fragment of Claim 234 and a physiologically acceptable vehicle or carrier.

244. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 234.

245. (New) The isolated cell of Claim 244, wherein said isolated cell is a hybridoma.

246. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO: 1 and the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for eotaxin.

Pub-G9

247. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.

248. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

249. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
250. (New) The antibody or antigen-binding fragment of Claim 246, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
251. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
252. (New) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
253. (New) The antibody or antigen-binding fragment of Claim 246, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
254. (New) A composition comprising the antibody or antigen-binding fragment of Claim 246 and a physiologically acceptable vehicle or carrier.

255. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 246.

256. (New) The isolated cell of Claim 255, wherein said isolated cell is a hybridoma.

*Pl
cont'd* 257. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for eotaxin.

258. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.

Sub 617 259. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

260. (New) The antibody or antigen-binding fragment of Claim 257, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

261. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

F1
Cmt'd

262. (New) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

263. (New) The antibody or antigen-binding fragment of Claim 257, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.

Rev G12

264. (New) A composition comprising the antibody or antigen-binding fragment of Claim 257 and a physiologically acceptable vehicle or carrier.

265. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 257.

266. (New) The isolated cell of Claim 265, wherein said isolated cell is a hybridoma.

267. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of

Fi
Cmt 4

SEQ ID NO:5, under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

268. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-2.
269. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-4.
270. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
271. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
272. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
273. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.

- F1
cont'd
274. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
275. (New) The antibody or antigen-binding fragment of Claim 267, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
276. (New) The antibody or antigen-binding fragment of Claim 267, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:5, the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
277. (New) A composition comprising the antibody or antigen-binding fragment of Claim 267 and a physiologically acceptable vehicle or carrier.
278. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 267.
279. (New) The isolated cell of Claim 278, wherein said isolated cell is a hybridoma.
280. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence

P1
Cont'd

of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

281. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-2.
282. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor has binding specificity for MCP-4.
283. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said naturally-occurring mammalian C-C chemokine receptor 3 protein.
284. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a mammalian C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
285. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is a naturally-occurring human C-C chemokine receptor 3 protein.
286. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

287. (New) The antibody or antigen-binding fragment of Claim 280, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
288. (New) The antibody or antigen-binding fragment of Claim 280, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of SEQ ID NO:3 or the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
289. (New) A composition comprising the antibody or antigen-binding fragment of Claim 280 and a physiologically acceptable vehicle or carrier.
290. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 280.
291. (New) The isolated cell of Claim 290, wherein said isolated cell is a hybridoma.
292. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.
293. (New) A composition comprising the antibody or antigen-binding fragment of Claim 292 and a physiologically acceptable vehicle or carrier.

F1
Cont'd

G

Ref 613

294. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 292.

295. (New) The isolated cell of Claim 294, wherein said isolated cell is a hybridoma.

296. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3 protein, wherein said naturally-occurring mammalian C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.

297. (New) A composition comprising the antibody or antigen-binding fragment of Claim 296 and a physiologically acceptable vehicle or carrier.

298. (New) An isolated cell that produces the antibody or antigen-binding fragment of Claim 296.

299. (New) The isolated cell of Claim 298, wherein said isolated cell is a hybridoma.

300. (New) Antibody 7B11 (ATCC Accession No. HB-12195) or an antigen binding fragment thereof.

301. (New) A composition comprising the antibody or antigen-binding fragment of Claim 300 and a physiologically acceptable vehicle or carrier.

302. (New) The hybridoma cell line deposited under ATCC Accession No. HB-12195.

303. (New) An antibody or antigen-binding fragment thereof having binding specificity for a naturally-occurring mammalian C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and